Non-oral drug delivery: Unlocking the full potential of protein degraders in cancer
Jean-Charles Soria, Amgen’s senior vice president of Oncology, shared an article by Matthew N. O’Brien Laramy on LinkedIn:
“Non-oral drug delivery options are key to deliver the full promise of protein degraders in cancer.
Nanoparticle-based delivery systems, peptide-based degraders, ADC-degraders, & long-acting injectables are some of the potential solutions.”
Delivering on the promise of protein degraders.
Authors: Matthew N. O’Brien Laramy, et al.
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023